U
TLOG

UBS’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

UBS’s Portfolio TLOG Stock Details TLOG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$17K Buy
4,056
+1,156
+40% +$5.39K ﹤0.01% 8243
2014
Q2 		$17K Buy
2,900
+1,800
+164% +$10.2K ﹤0.01% 8311
2014
Q1 		$7K Sell
1,100
-802
-42% -$7.23K ﹤0.01% 9305
2013
Q4 		$18K Buy
+1,902
New +$14.8K ﹤0.01% 8304

Other funds holding TLOG

CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
FWC
First Washington Corp Seattle, Washington $353M AUM 41.46% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

UBS's TLOG Position: Q3 2014 in Review

UBS increased its TetraLogic Pharmaceuticals Corporation (TLOG) stake by 40% in Q3 2014, buying an estimated $5.39K and bringing the position to 4,056 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #8243.

UBS first reported a position in TLOG in Q4 2013 and has held it in 4 quarters since. The position peaked at $18K in Q4 2013. 25 funds tracked by Wall St. Rank hold TLOG as of Q3 2014.

  • UBS held 4,056 shares of TetraLogic Pharmaceuticals Corporation worth $17K as of Q3 2014.
  • UBS bought 1,156 TetraLogic Pharmaceuticals Corporation shares in Q3 2014, an estimated $5.39K.
  • TetraLogic Pharmaceuticals Corporation made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8243 holding.
  • UBS first reported a position in TetraLogic Pharmaceuticals Corporation in Q4 2013 and has held it in 4 quarters since.
  • UBS's TetraLogic Pharmaceuticals Corporation position peaked at $18K in Q4 2013.
  • 25 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.